# A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging

> **NCT04038957** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SEP-363856

## Key facts

- **NCT ID:** NCT04038957
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-07
- **Primary completion:** 2023-06-06
- **Final completion:** 2023-06-06
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04038957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04038957, "A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) Imaging". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04038957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*